Jula K Inrig
Overview
Explore the profile of Jula K Inrig including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mariani L, Trachtman H, Thompson A, Gillespie B, Denburg M, Diva U, et al.
Am J Kidney Dis
. 2024 Oct;
PMID: 39455047
Focal segmental glomerulosclerosis (FSGS) is a characteristic histopathological lesion that is indicative of underlying glomerular dysfunction. It is not a single disease entity but rather a heterogeneous disorder that is...
2.
Rovin B, Barratt J, Heerspink H, Alpers C, Bieler S, Chae D, et al.
Lancet
. 2023 Nov;
402(10417):2077-2090.
PMID: 37931634
Background: Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin...
3.
Rheault M, Alpers C, Barratt J, Bieler S, Canetta P, Chae D, et al.
N Engl J Med
. 2023 Nov;
389(26):2436-2445.
PMID: 37921461
Background: An unmet need exists for focal segmental glomerulosclerosis (FSGS) treatment. In an 8-week, phase 2 trial, sparsentan, a dual endothelin-angiotensin receptor antagonist, reduced proteinuria in patients with FSGS. The...
4.
Narasaki Y, Okuda Y, Moore L, You A, Tantisattamo E, Inrig J, et al.
Am J Clin Nutr
. 2021 Mar;
114(1):303-313.
PMID: 33742197
Background: High-protein diets (e.g., Paleo, Atkins, South Beach, ketogenic) have gained popularity as a means to promote weight loss and avoid excess carbohydrate consumption. Yet in chronic kidney disease (CKD)...
5.
Komers R, Diva U, Inrig J, Loewen A, Trachtman H, Rote W
Kidney Int Rep
. 2020 Apr;
5(4):494-502.
PMID: 32274453
Introduction: Focal segmental glomerulosclerosis (FSGS), a histologic lesion in the kidney caused by varied pathophysiological processes, leads to end-stage kidney disease in a large proportion of patients. Sparsentan is a...
6.
7.
Van Buren P, Inrig J
Semin Dial
. 2017 Jul;
30(6):545-552.
PMID: 28666072
Hypertension is a comorbidity that is present in the majority of end-stage renal disease patients on maintenance hemodialysis. This population is particularly unique because of the dynamic nature of blood...
8.
Chou J, Streja E, Nguyen D, Rhee C, Obi Y, Inrig J, et al.
Nephrol Dial Transplant
. 2017 Apr;
33(1):149-159.
PMID: 28444336
Background: Intradialytic hypotension (IDH) occurs frequently in maintenance hemodialysis (HD) patients and may be associated with higher mortality. We hypothesize that nadir intradialytic systolic blood pressure (niSBP) is inversely related...
9.
Linde P, Archdeacon P, Breyer M, Ibrahim T, Inrig J, Kewalramani R, et al.
J Am Soc Nephrol
. 2016 Apr;
27(7):1902-10.
PMID: 27127187
Innovation in kidney diseases is not commensurate with the effect of these diseases on human health and mortality or innovation in other key therapeutic areas. A primary cause of the...
10.
Van Buren P, Inrig J
Blood Purif
. 2016 Jan;
41(1-3):188-93.
PMID: 26765312
Background: Intradialytic hypertension is a condition where there is an increase in blood pressure (BP) from pre- to post-hemodialysis; this condition has been recently identified as an independent mortality risk...